Loading...

Vext Science, Inc.

VEXTFPNK
Healthcare
Drug Manufacturers - Specialty & Generic
$0.27
$-0.02(-7.02%)
U.S. Market opens in 55h 58m

Vext Science, Inc. Fundamental Analysis

Vext Science, Inc. (VEXTF) shows moderate financial fundamentals with a PE ratio of -2.75, profit margin of -35.21%, and ROE of -27.18%. The company generates $0.1B in annual revenue with moderate year-over-year growth of 3.40%.

Key Strengths

Cash Position10.31%
PEG Ratio-0.15

Areas of Concern

ROE-27.18%
Operating Margin-16.42%
Current Ratio0.59
We analyze VEXTF's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -33.5/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-33.5/100

We analyze VEXTF's fundamental strength across five key dimensions:

Efficiency Score

Weak

VEXTF struggles to generate sufficient returns from assets.

ROA > 10%
-15.09%

Valuation Score

Excellent

VEXTF trades at attractive valuation levels.

PE < 25
-2.75
PEG Ratio < 2
-0.15

Growth Score

Weak

VEXTF faces weak or negative growth trends.

Revenue Growth > 5%
3.40%
EPS Growth > 10%
-4.49%

Financial Health Score

Moderate

VEXTF shows balanced financial health with some risks.

Debt/Equity < 1
0.63
Current Ratio > 1
0.59

Profitability Score

Weak

VEXTF struggles to sustain strong margins.

ROE > 15%
-2718.09%
Net Margin ≥ 15%
-35.21%
Positive Free Cash Flow
Yes

Key Financial Metrics

Is VEXTF Expensive or Cheap?

P/E Ratio

VEXTF trades at -2.75 times earnings. This suggests potential undervaluation.

-2.75

PEG Ratio

When adjusting for growth, VEXTF's PEG of -0.15 indicates potential undervaluation.

-0.15

Price to Book

The market values Vext Science, Inc. at 0.90 times its book value. This may indicate undervaluation.

0.90

EV/EBITDA

Enterprise value stands at 4.65 times EBITDA. This is generally considered low.

4.65

How Well Does VEXTF Make Money?

Net Profit Margin

For every $100 in sales, Vext Science, Inc. keeps $-35.21 as profit after all expenses.

-35.21%

Operating Margin

Core operations generate -16.42 in profit for every $100 in revenue, before interest and taxes.

-16.42%

ROE

Management delivers $-27.18 in profit for every $100 of shareholder equity.

-27.18%

ROA

Vext Science, Inc. generates $-15.09 in profit for every $100 in assets, demonstrating efficient asset deployment.

-15.09%

Following the Money - Real Cash Generation

Operating Cash Flow

Vext Science, Inc. produces operating cash flow of $15.68M, showing steady but balanced cash generation.

$15.68M

Free Cash Flow

Vext Science, Inc. generates strong free cash flow of $10.91M, providing ample flexibility for dividends, buybacks, or growth.

$10.91M

FCF Per Share

Each share generates $0.04 in free cash annually.

$0.04

FCF Yield

VEXTF converts 12.47% of its market value into free cash.

12.47%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-2.75

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.15

vs 25 benchmark

P/B Ratio

Price to book value ratio

0.90

vs 25 benchmark

P/S Ratio

Price to sales ratio

1.29

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.63

vs 25 benchmark

Current Ratio

Current assets to current liabilities

0.59

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.27

vs 25 benchmark

ROA

Return on assets percentage

-0.15

vs 25 benchmark

ROCE

Return on capital employed

-0.09

vs 25 benchmark

How VEXTF Stacks Against Its Sector Peers

MetricVEXTF ValueSector AveragePerformance
P/E Ratio-2.7529.29 Better (Cheaper)
ROE-27.18%690.00% Weak
Net Margin-35.21%-45102.00% (disorted) Weak
Debt/Equity0.630.43 Weak (High Leverage)
Current Ratio0.594.48 Weak Liquidity
ROA-15.09%-14932.00% (disorted) Weak

VEXTF outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Vext Science, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-43.53%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

-381.26%

Industry Style: Defensive, Growth, Innovation

Declining

FCF CAGR

392.79%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ